JPH07119207B2 - Phenylthioalkylcarboxylic acid derivative - Google Patents
Phenylthioalkylcarboxylic acid derivativeInfo
- Publication number
- JPH07119207B2 JPH07119207B2 JP21189090A JP21189090A JPH07119207B2 JP H07119207 B2 JPH07119207 B2 JP H07119207B2 JP 21189090 A JP21189090 A JP 21189090A JP 21189090 A JP21189090 A JP 21189090A JP H07119207 B2 JPH07119207 B2 JP H07119207B2
- Authority
- JP
- Japan
- Prior art keywords
- acid
- general formula
- acid derivative
- dipentylcarbamoyl
- phenylthioalkylcarboxylic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000002253 acid Substances 0.000 title description 18
- 125000000217 alkyl group Chemical group 0.000 claims description 7
- 125000004432 carbon atom Chemical group C* 0.000 claims description 7
- 229910052799 carbon Inorganic materials 0.000 claims description 4
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
- -1 alkali metal salt Chemical group 0.000 description 16
- 239000000243 solution Substances 0.000 description 16
- 239000002904 solvent Substances 0.000 description 15
- 150000001875 compounds Chemical class 0.000 description 14
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 12
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 8
- 238000003818 flash chromatography Methods 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 239000000741 silica gel Substances 0.000 description 8
- 229910002027 silica gel Inorganic materials 0.000 description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 206010033645 Pancreatitis Diseases 0.000 description 5
- 206010033647 Pancreatitis acute Diseases 0.000 description 5
- 201000003229 acute pancreatitis Diseases 0.000 description 5
- 208000003770 biliary dyskinesia Diseases 0.000 description 5
- 206010009887 colitis Diseases 0.000 description 5
- 229910052739 hydrogen Inorganic materials 0.000 description 5
- 229940124597 therapeutic agent Drugs 0.000 description 5
- 102000004859 Cholecystokinin Receptors Human genes 0.000 description 4
- 108090001085 Cholecystokinin Receptors Proteins 0.000 description 4
- 230000003042 antagnostic effect Effects 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 238000002844 melting Methods 0.000 description 4
- 230000008018 melting Effects 0.000 description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 4
- QKOSUQDUCCGQAV-UHFFFAOYSA-N 2-[(3,4-dimethylphenyl)sulfanylmethyl]-5-methoxy-5-oxopentanoic acid Chemical compound COC(=O)CCC(C(O)=O)CSC1=CC=C(C)C(C)=C1 QKOSUQDUCCGQAV-UHFFFAOYSA-N 0.000 description 3
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 3
- LOBVDTHAUQDXAQ-UHFFFAOYSA-N 4-[(3,4-dimethylphenyl)sulfinylmethyl]-5-(dipentylamino)-5-oxopentanoic acid Chemical compound CCCCCN(CCCCC)C(=O)C(CCC(O)=O)CS(=O)C1=CC=C(C)C(C)=C1 LOBVDTHAUQDXAQ-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 238000000921 elemental analysis Methods 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000003301 hydrolyzing effect Effects 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 3
- GGGYDPKDZOVTLM-UHFFFAOYSA-N 2-[(3,4-dimethylphenyl)sulfanylmethyl]pentanedioic acid Chemical compound CC1=CC=C(SCC(CCC(O)=O)C(O)=O)C=C1C GGGYDPKDZOVTLM-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- RKOTXQYWCBGZLP-UHFFFAOYSA-N N-[(2,4-difluorophenyl)methyl]-2-ethyl-9-hydroxy-3-methoxy-1,8-dioxospiro[3H-pyrido[1,2-a]pyrazine-4,3'-oxolane]-7-carboxamide Chemical compound CCN1C(OC)C2(CCOC2)N2C=C(C(=O)NCC3=C(F)C=C(F)C=C3)C(=O)C(O)=C2C1=O RKOTXQYWCBGZLP-UHFFFAOYSA-N 0.000 description 2
- FQJSWFYPNWZWHC-UHFFFAOYSA-N methyl 4-[(3,4-dimethylphenyl)sulfanylmethyl]-5-(dipentylamino)-5-oxopentanoate Chemical compound CCCCCN(CCCCC)C(=O)C(CCC(=O)OC)CSC1=CC=C(C)C(C)=C1 FQJSWFYPNWZWHC-UHFFFAOYSA-N 0.000 description 2
- HNBDRPTVWVGKBR-UHFFFAOYSA-N methyl pentanoate Chemical compound CCCCC(=O)OC HNBDRPTVWVGKBR-UHFFFAOYSA-N 0.000 description 2
- 239000007800 oxidant agent Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 2
- 235000010265 sodium sulphite Nutrition 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- NICCSHFMHHBRNI-UHFFFAOYSA-N 2-[(3,4-dimethylphenyl)sulfanylmethyl]pentanedinitrile Chemical compound CC1=CC=C(SCC(CCC#N)C#N)C=C1C NICCSHFMHHBRNI-UHFFFAOYSA-N 0.000 description 1
- NGCJVMZXRCLPRQ-UHFFFAOYSA-N 2-methylidenepentanedinitrile Chemical compound N#CC(=C)CCC#N NGCJVMZXRCLPRQ-UHFFFAOYSA-N 0.000 description 1
- IDKCKPBAFOIONK-UHFFFAOYSA-N 3,4-dimethylbenzenethiol Chemical compound CC1=CC=C(S)C=C1C IDKCKPBAFOIONK-UHFFFAOYSA-N 0.000 description 1
- 229940122623 CCK receptor antagonist Drugs 0.000 description 1
- 101800001982 Cholecystokinin Proteins 0.000 description 1
- 102100025841 Cholecystokinin Human genes 0.000 description 1
- 102100021022 Gastrin Human genes 0.000 description 1
- 108010052343 Gastrins Proteins 0.000 description 1
- 239000002879 Lewis base Substances 0.000 description 1
- 108010086019 Secretin Proteins 0.000 description 1
- 102100037505 Secretin Human genes 0.000 description 1
- 108010087230 Sincalide Proteins 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- NDKBVBUGCNGSJJ-UHFFFAOYSA-M benzyltrimethylammonium hydroxide Chemical compound [OH-].C[N+](C)(C)CC1=CC=CC=C1 NDKBVBUGCNGSJJ-UHFFFAOYSA-M 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000010609 cell counting kit-8 assay Methods 0.000 description 1
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical group C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 description 1
- OQNGCCWBHLEQFN-UHFFFAOYSA-N chloroform;hexane Chemical compound ClC(Cl)Cl.CCCCCC OQNGCCWBHLEQFN-UHFFFAOYSA-N 0.000 description 1
- 229940107137 cholecystokinin Drugs 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000012156 elution solvent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- ZKQFHRVKCYFVCN-UHFFFAOYSA-N ethoxyethane;hexane Chemical compound CCOCC.CCCCCC ZKQFHRVKCYFVCN-UHFFFAOYSA-N 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 239000003629 gastrointestinal hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 239000011968 lewis acid catalyst Substances 0.000 description 1
- 150000007527 lewis bases Chemical class 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- JACMPVXHEARCBO-UHFFFAOYSA-N n-pentylpentan-1-amine Chemical compound CCCCCNCCCCC JACMPVXHEARCBO-UHFFFAOYSA-N 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229960002101 secretin Drugs 0.000 description 1
- OWMZNFCDEHGFEP-NFBCVYDUSA-N secretin human Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(N)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)C1=CC=CC=C1 OWMZNFCDEHGFEP-NFBCVYDUSA-N 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- RMVRSNDYEFQCLF-UHFFFAOYSA-N thiophenol Chemical class SC1=CC=CC=C1 RMVRSNDYEFQCLF-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Description
【発明の詳細な説明】 産業上の利用分野 本発明は医薬品の製造中間体として有用な、一般式 (式中のR1およびR2は同じでも異なっていてもよく、そ
れぞれ炭素数1〜10のアルキル基であり、R3は水素原子
または炭素数1〜4のアルキル基であり、Xは炭素数1
〜3のアルキル基、ニトロ基およびアセチル基の中から
選ばれる基であり、nは1または2である)で表される
フェニルチオアルキルカルボン酸誘導体に関するもので
ある。TECHNICAL FIELD The present invention relates to a general formula useful as an intermediate for the manufacture of pharmaceuticals. (R 1 and R 2 in the formula may be the same or different and each is an alkyl group having 1 to 10 carbon atoms, R 3 is a hydrogen atom or an alkyl group having 1 to 4 carbon atoms, and X is a carbon atom. Number 1
~ 3 is a group selected from an alkyl group, a nitro group, and an acetyl group, and n is 1 or 2), and a phenylthioalkylcarboxylic acid derivative.
さらに詳しく述べれば、本発明は、コレシストキニン
(cholecystokinin、以下CCKという)受容体拮抗作用を
示し、過敏性大腸炎、胆道ジスキネジー、急性膵炎など
の疾患の予防および治療剤として有用な、一般式 (式中のYはスルホニル基またはスルフィニル基であ
り、R1、R2、X、mおよびnは前記と同じ意味をもつ)
で表されるフェニルスルホニルアルキルカルボン酸誘導
体およびフェニルスルフィニルアルキルカルボン酸誘導
体の製造中間体として有用な一般式(I)で表されるフ
ェニルチオアルキルカルボン酸誘導体に関するものであ
る。More specifically, the present invention shows a cholecystokinin (hereinafter referred to as CCK) receptor antagonistic action, and is useful as a prophylactic and therapeutic agent for diseases such as irritable colitis, biliary dyskinesia, and acute pancreatitis. (In the formula, Y is a sulfonyl group or a sulfinyl group, and R 1 , R 2 , X, m and n have the same meanings as described above.)
The present invention relates to a phenylthioalkylcarboxylic acid derivative represented by the general formula (I) which is useful as an intermediate for the production of phenylsulfonylalkylcarboxylic acid derivatives and phenylsulfinylalkylcarboxylic acid derivatives.
従来の技術 CCKはガストリン(gastrin)、セクレチン(secretin)
と並ぶ代表的な消化管ホルモンで、特に膵外分泌刺激、
胆嚢収縮等に関与するホルモンであることが知られてい
る。Conventional technology CCK is gastrin, secretin
It is a typical gastrointestinal hormone along with, especially pancreatic exocrine stimulation,
It is known to be a hormone involved in gallbladder contraction and the like.
近年、CCKに関する研究が進められ、各種疾患におけるS
SKの関与について解明されてきた。In recent years, research on CCK has been advanced, and SCK in various diseases has been investigated.
The involvement of SK has been elucidated.
その結果、特異的、競合的かつ可逆的なCCK受容体拮抗
剤が過敏性大腸炎、胆道ジスキネジー、急性膵炎などの
疾患の予防および治療剤として期待されるようになり、
注目を集めている。As a result, specific, competitive and reversible CCK receptor antagonists have come to be expected as preventive and therapeutic agents for diseases such as irritable colitis, biliary dyskinesia, and acute pancreatitis,
It is getting attention.
発明が解決しようとする課題 本発明の目的は、CCK受容体拮抗作用を有し、過敏性大
腸炎、胆道ジスキネジー、急性膵炎などの疾患の予防お
よび治療剤として有用な前記一般式(II)で表されるフ
ェニルスルホニルアルキルカルボン酸誘導体およびフェ
ニルスルフィニルアルキルカルボン酸誘導体の製造中間
体として有用な前記一般式(I)で表されるフェニルチ
オアルキルカルボン酸誘導体を提供することである。The object of the present invention is to have a CCK receptor antagonistic action, in the general formula (II) useful as a prophylactic and therapeutic agent for diseases such as irritable colitis, biliary dyskinesia, acute pancreatitis and the like. It is an object of the present invention to provide a phenylthioalkylcarboxylic acid derivative represented by the general formula (I), which is useful as an intermediate for the production of the phenylsulfonylalkylcarboxylic acid derivative and the phenylsulfinylalkylcarboxylic acid derivative.
課題を解決するための手段 前記一般式(II)で表されるフェニルスルホニルアルキ
ルカルボン酸誘導体およびフェニルスルフィニルアルキ
ルカルボン酸誘導体は強力なCCK受容体拮抗作用を有
し、過敏性大腸炎、胆道ジスキネジー、急性膵炎などの
疾患の予防および治療剤として有用である。Means for Solving the Problems The phenylsulfonylalkylcarboxylic acid derivative and the phenylsulfinylalkylcarboxylic acid derivative represented by the general formula (II) have a strong CCK receptor antagonistic action, irritable colitis, biliary dyskinesia, It is useful as a prophylactic and therapeutic agent for diseases such as acute pancreatitis.
本発明の前記一般式(I)で表されるフェニルチオアル
キルカルボン酸誘導体は、これを適当な酸化剤で酸化
し、必要に応じ加水分解することにより、きわめて容易
に収率よく前記一般式(II)の化合物に導くことができ
る。The phenylthioalkylcarboxylic acid derivative represented by the general formula (I) of the present invention can be very easily produced in good yield by oxidizing the compound with a suitable oxidizing agent and hydrolyzing it if necessary. It can lead to the compound of II).
本発明の一般式(I)で表されるフェニルチオアルキル
カルボン酸誘導体は新規な化合物であり、以下のように
して製造することができる。The phenylthioalkylcarboxylic acid derivative represented by the general formula (I) of the present invention is a novel compound and can be produced as follows.
すなわち、一般式 (式中のR4は炭素数1〜4のアルキル基であり、Xおよ
びnは前記と同じ意味をもつ)で表されるフェニルチオ
アルキルカルボン酸誘導体またはその反応性官能的誘導
体と、一般式 (式中のR1およびR2は前記と同じ意味をもつ)で表され
るアミン類とを反応させ、必要に応じて加水分解するこ
により製造することができる。That is, the general formula (Wherein R 4 is an alkyl group having 1 to 4 carbon atoms, and X and n have the same meanings as described above), and a phenylthioalkylcarboxylic acid derivative or a reactive functional derivative thereof; (R 1 and R 2 in the formula have the same meaning as described above), and can be produced by reacting with an amine and optionally hydrolyzing.
本発明の一般式(I)の化合物の製造方法において出発
原料として用いられる前記一般式(III)の化合物は新
規化合物であり、以下のようにして製造することができ
る。The compound of the general formula (III) used as a starting material in the method for producing the compound of the general formula (I) of the present invention is a novel compound and can be produced as follows.
すなわち、一般式 (式中のXおよびnは前記と同じ意味をもつ)で表され
るチオフェノール誘導体と、一般式 (式中のAおよびBはそれぞれシアノ基または炭素数2
〜5のアルコキシカルボニル基であるかあるいはAが炭
素数2〜5のアルコキシカルボニル基でBがカルボキシ
基またはそのアルカリ金属塩である)で表される化合物
とをルイス塩基またはルイス酸触媒の存在下に反応し
て、一般式 (式中のA、B、Xおよびnは前記と同じ意味をもつ)
で表される化合物を製し、必要に応じこれを適当な方法
により加水分解、モノエステル化を行うことにより得る
ことができる。That is, the general formula (Wherein X and n have the same meanings as described above), a thiophenol derivative represented by the general formula (A and B in the formula are each a cyano group or a carbon number of 2
A compound represented by the formula (1) to (5) or (A is an alkoxycarbonyl group having 2 to 5 carbon atoms and B is a carboxy group or an alkali metal salt thereof) in the presence of a Lewis base or a Lewis acid catalyst. In response to the general formula (A, B, X and n in the formula have the same meanings as described above)
It can be obtained by producing a compound represented by and hydrolyzing and monoesterifying it by an appropriate method, if necessary.
本発明の一般式(I)で表されるフェニルチオアルキル
カルボン酸誘導体は不斉炭素を有しており、2種の光学
異性体が存在するが、本発明においてはR体、S体また
はその混合物のいずれも含まれる。The phenylthioalkylcarboxylic acid derivative represented by the general formula (I) of the present invention has an asymmetric carbon and has two kinds of optical isomers. Any mixture is included.
発明の効果 本発明の一般式(I)で表されるフェニルチオアルキル
カルボン酸誘導体は、適当な酸化剤、例えば、m−クロ
ロ過安息香酸を用いて酸化し、必要に応じて加水分解す
ることにより極めて容易に、収率よく一般式(II)で表
されるフェニルスルホニルアルキルカルボン酸誘導体お
よびフェニルスルフィニルアルキルカルボン酸誘導体に
導くことができる。EFFECTS OF THE INVENTION The phenylthioalkylcarboxylic acid derivative represented by the general formula (I) of the present invention should be oxidized with a suitable oxidizing agent, for example, m-chloroperbenzoic acid, and hydrolyzed as necessary. With this, it is possible to very easily lead to a phenylsulfonylalkylcarboxylic acid derivative and a phenylsulfinylalkylcarboxylic acid derivative represented by the general formula (II) with high yield.
このようにして、本発明の一般式(I)の化合物から製
造される一般式(II)で表される化合物はCCK受容体拮
抗作用を有し、過敏性大腸炎、胆道ジスキネジー、急性
膵炎などの疾患治療剤として有用である。As described above, the compound represented by the general formula (II) produced from the compound of the general formula (I) of the present invention has a CCK receptor antagonistic action, and is susceptible to irritable colitis, biliary dyskinesia, acute pancreatitis, etc. It is useful as a therapeutic agent for the disease.
例えば、125IでラベルしたCCK−8を用いたラット摘出
膵臓のCCK受容体に対するバインディングアッセイにお
いて、5−(3,4−ジメチルフェニルスルホニル)−4
−(N,N−ジペンチルカルバモイル)ペンタン酸および
5−(3,4−ジメチルフェニルスルフィニル)−4−
(N,N−ジペンチルカルバモイル)ペンタン酸はそれぞ
れ2.9×10-7モル濃度、1.4×10-7モル濃度で50%結合抑
制(IC50)を示す。For example, in a binding assay for CCK receptor in rat isolated pancreas using CCK-8 labeled with 125 I, 5- (3,4-dimethylphenylsulfonyl) -4 was obtained.
-(N, N-dipentylcarbamoyl) pentanoic acid and 5- (3,4-dimethylphenylsulfinyl) -4-
(N, N-dipentylcarbamoyl) pentanoic acid exhibits 50% binding inhibition (IC 50 ) at 2.9 × 10 −7 molar concentration and 1.4 × 10 −7 molar concentration, respectively.
実施例 本発明の内容を以下の参考例および実施例でさらに詳細
に説明する。なお、各参考例および実施例中の化合物の
融点はすべて未補正である。EXAMPLES The contents of the present invention will be described in more detail with reference to the following reference examples and examples. The melting points of the compounds in Reference Examples and Examples are all uncorrected.
参考例1 2−(3,4−ジメチルフェニルチオメチル)−4−メト
キシカルボニル酪酸 3,4−ジメチルベンゼンチオール0.59mlと2−メチレン
グルタロニトリル0.48mlをエタノール10mlに溶かし、ト
リトンB(40%メタノール溶液)5滴を加えたのち5時
間加熱還流させた。反応液を減圧下に濃縮後、クロロホ
ルムで抽出し水洗いしたのち無水硫酸マグネシウムで乾
燥した。減圧下に溶媒を留去後、残留物をシリカゲルフ
ラッシュカラムクロマトグラフィー(溶出溶媒:ベンゼ
ン/酢酸エチル=7/1)で精製し、油状の2−(3,4−ジ
メチルフェニルチオメチル)グルタロニトリル1.18gを
得た。Reference Example 1 2- (3,4-Dimethylphenylthiomethyl) -4-methoxycarbonylbutyric acid 0.54 ml of 3,4-dimethylbenzenethiol and 0.48 ml of 2-methyleneglutaronitrile were dissolved in 10 ml of ethanol, and Triton B (40%) was added. After adding 5 drops of methanol solution, the mixture was heated under reflux for 5 hours. The reaction mixture was concentrated under reduced pressure, extracted with chloroform, washed with water, and dried over anhydrous magnesium sulfate. After evaporating the solvent under reduced pressure, the residue was purified by silica gel flash column chromatography (eluting solvent: benzene / ethyl acetate = 7/1) to give oily 2- (3,4-dimethylphenylthiomethyl) glutaro. 1.18 g of nitrile was obtained.
IR(neat):νCN2230cm-1 NMR(CDC13) δ:1.9〜2.35(8H,m),2.45〜2.7(2H,m),2.85〜2.9
(1H,m),2.98(1H,dd,J=7.7,13.7Hz),3.18(1H,dd,J
=6.6,13.7Hz),7.11(1H,d,J=7.7Hz),7.19(1H,dd,J
=1.7,7.7Hz),7.24(1H,d,J=1.7Hz) 2−(3,4−ジメチルフェニルチオメチル)グルタロニ
トリル1.16gを酢酸8mlに溶かし、濃塩酸8mlを加え19時
間加熱還流させた。反応液を減圧下に濃縮しジエチルエ
ーテルを加え不溶物をろ去後、水洗いしたのち炭酸水素
ナトリウム水溶液を加え振り混ぜた。水層を塩酸で酸性
としたのち、ジエチルエーテルで抽出し水洗後無水硫酸
マグネシウムで乾燥した。減圧下に溶媒を留去し、残留
物をジエチルエーテル−ヘキサンより再結晶し、融点96
〜98℃の2−(3,4−ジメチルフェニルチオメチル)グ
ルタル酸1.18gを得た。 IR (neat): ν CN 2230cm -1 NMR (CDC1 3) δ: 1.9~2.35 (8H, m), 2.45~2.7 (2H, m), 2.85~2.9
(1H, m), 2.98 (1H, dd, J = 7.7,13.7Hz), 3.18 (1H, dd, J
= 6.6,13.7Hz), 7.11 (1H, d, J = 7.7Hz), 7.19 (1H, dd, J
= 1.7,7.7Hz), 7.24 (1H, d, J = 1.7Hz) 2- (3,4-dimethylphenylthiomethyl) glutaronitrile 1.16g is dissolved in acetic acid 8ml, concentrated hydrochloric acid 8ml is added and refluxed for 19 hours. Let The reaction solution was concentrated under reduced pressure, diethyl ether was added, the insoluble material was filtered off, washed with water, then an aqueous sodium hydrogen carbonate solution was added, and the mixture was shaken. The aqueous layer was acidified with hydrochloric acid, extracted with diethyl ether, washed with water, and dried over anhydrous magnesium sulfate. The solvent was distilled off under reduced pressure, and the residue was recrystallized from diethyl ether-hexane to give a melting point of 96.
Obtained 1.18 g of 2- (3,4-dimethylphenylthiomethyl) glutaric acid at -98 ° C.
元素分析値:(C14H18O4Sとして) C% H% 計算値 59.55 6.43 実測値 59.38 6.56 IR(KBr):νC=O1705cm-1 NMR(DMS0−d6) δ:1.65〜1.95(2H,m),2.1〜2.55(9H,m),3.04(2
H,d,J=7.2Hz),7.0〜7.2(3H,m),12.28(2H,s) 2−(3,4−ジメチルフェニルチオメチル)グルタル酸
1.16gをメタノール20mlに溶かし、p−トルエンスルホ
ン酸0.04gを加え40℃で撹拌下に1.5時間反応させた。反
応液を減圧下に濃縮後、残留物をシリカゲルフラッシュ
カラムクロマトグラフィー(溶出溶媒:クロロホルム/
エタノール=10/1)で精製し、油状の2−(3,4−ジメ
チルフェニルチオメチル)−4−メトキシカルボニル酪
酸0.98gを得た。Elemental analysis value: (as C 14 H 18 O 4 S) C% H% Calculated value 59.55 6.43 Measured value 59.38 6.56 IR (KBr): ν C = O 1705 cm -1 NMR (DMS0-d 6 ) δ: 1.65 to 1.95 (2H, m), 2.1 ~ 2.55 (9H, m), 3.04 (2
H, d, J = 7.2Hz), 7.0-7.2 (3H, m), 12.28 (2H, s) 2- (3,4-dimethylphenylthiomethyl) glutaric acid
1.16 g was dissolved in 20 ml of methanol, 0.04 g of p-toluenesulfonic acid was added, and the mixture was reacted at 40 ° C. for 1.5 hours with stirring. The reaction solution was concentrated under reduced pressure, and the residue was subjected to silica gel flash column chromatography (elution solvent: chloroform /
Purification with ethanol = 10/1) gave 0.98 g of oily 2- (3,4-dimethylphenylthiomethyl) -4-methoxycarbonylbutyric acid.
IR(neat):νC=01735,1705cm-1 NMR(CDC13) δ:1.9〜2.5(10H,m),2.55〜2.7(1H,m),2.94(1H,
dd,J=6.6,13.7Hz),3.19(1H,dd,J=7.7,13.7Hz),3.6
5(3H,s),7.06(1H,d,J=7.7Hz),7.1〜7.2(2H,m) 参考例2 参考例1と同様にして表の化合物を製造した。 IR (neat): ν C = 0 1735,1705cm -1 NMR (CDC1 3) δ: 1.9~2.5 (10H, m), 2.55~2.7 (1H, m), 2.94 (1H,
dd, J = 6.6,13.7Hz), 3.19 (1H, dd, J = 7.7,13.7Hz), 3.6
5 (3H, s), 7.06 (1H, d, J = 7.7Hz), 7.1 to 7.2 (2H, m) Reference Example 2 The compounds in the table were produced in the same manner as in Reference Example 1.
実施例1 5−(3,4−ジメチルフェニルチオ)−4−(N,N−ジペ
ンチルカルバモイル)ペンタン酸メチル 2−(3,4−ジメチルフェニルチオメチル)−4−メト
キシカルボニル酪酸0.50gを乾燥ベンゼン6mlに溶かし、
塩化チオニル0.2mlを加え2時間加熱還流させた。反応
液を減圧下に濃縮乾固し油状の残留物を得た。この残留
物の乾燥塩化メチレン4ml溶液を、ジペンチルアミン0.3
5mlおよびトリエチルアミン0.3mlの乾燥塩化メチレン2m
l溶液に氷冷撹拌下に滴下したのち室温で5時間反応さ
せた。反応液を希塩酸、水、炭酸水素ナトリウム水溶液
および水で順次洗ったのち無水硫酸マグネシウムで乾燥
した。減圧下に溶媒を留去後、残留物をシリカゲルフラ
ッシュカラムクロマトグラフィー(溶出溶媒:クロロホ
ル)で精製し、油状の5−(3,4−ジメチルフェニルチ
オ)−4−(N,N−ジペンチルカルバモイル)ペンタン
酸メチル0.76gを得た。 Example 1 Methyl 5- (3,4-dimethylphenylthio) -4- (N, N-dipentylcarbamoyl) pentanoate 0.50 g of 2- (3,4-dimethylphenylthiomethyl) -4-methoxycarbonylbutyric acid was dried. Dissolve in 6 ml of benzene,
Thionyl chloride (0.2 ml) was added and the mixture was heated under reflux for 2 hours. The reaction solution was concentrated to dryness under reduced pressure to obtain an oily residue. A solution of this residue in dry methylene chloride (4 ml) was added to dipentylamine (0.3 ml).
2 ml of dry methylene chloride of 5 ml and triethylamine 0.3 ml
The solution was added dropwise to the solution with stirring under ice-cooling and then reacted at room temperature for 5 hours. The reaction solution was washed successively with diluted hydrochloric acid, water, an aqueous solution of sodium hydrogen carbonate and water, and then dried over anhydrous magnesium sulfate. After evaporating the solvent under reduced pressure, the residue was purified by silica gel flash column chromatography (eluting solvent: chloroform) to give oily 5- (3,4-dimethylphenylthio) -4- (N, N-dipentylcarbamoyl). ) 0.76 g of methyl pentanoate was obtained.
IR(neat):νC=O1730,1635cm-1 NMR(CDC13) δ:0.84(3H,t,J=6.6Hz),0.89(3H,t,J=6.6Hz),
0.95〜1.6(12H,m),1.95〜2.1(2H,m),2.15〜2.5(8
H,m),2.8〜3.4(7H,m),3.65(3H,s),7.0〜7.2(3H,
m) 実施例2 実施例1と同様にして表の化合物(油状)を製造した。IR (neat): ν C = O 1730,1635 cm -1 NMR (CDC1 3 ) δ: 0.84 (3H, t, J = 6.6Hz), 0.89 (3H, t, J = 6.6Hz),
0.95 ~ 1.6 (12H, m), 1.95 ~ 2.1 (2H, m), 2.15 ~ 2.5 (8
H, m), 2.8 ~ 3.4 (7H, m), 3.65 (3H, s), 7.0 ~ 7.2 (3H,
m) Example 2 In the same manner as in Example 1, the compounds in the table (oil) were produced.
実施例3 5−(3,4−ジメチルフェニルチオ)−4−(N,N−ジペ
ンチルカルバモイル)ペンタン酸 5−(3,4−ジメチルフェニルチオ)−4−(N,N−ジペ
ンチルカルバモイル)ペンタン酸メチル150mgをエタノ
ール6mlに溶かし、1規定水酸化ナトリウム水溶液0.35m
lを加え室温で4時間反応させた。反応液を減圧下に濃
縮後、希塩酸で酸性としクロロホルムで抽出し、水洗後
無水硫酸マグネシウムで乾燥した。減圧下に溶媒を留去
後、残留物をシリカゲルフラッシュカラムクロマトグラ
フィー(溶出溶媒:クロロホルム/エタノール=20/1)
で精製し、油状の5−(3,4−ジメチルフェニルチオ)
−4−(N,N−ジペンチルカルバモイル)ペンタン酸124
mgを得た。 Example 3 5- (3,4-Dimethylphenylthio) -4- (N, N-dipentylcarbamoyl) pentanoic acid 5- (3,4-Dimethylphenylthio) -4- (N, N-dipentylcarbamoyl) pentane Dissolve 150 mg of methyl acid in 6 ml of ethanol, 0.35 m of 1N sodium hydroxide solution
l was added and reacted at room temperature for 4 hours. The reaction solution was concentrated under reduced pressure, acidified with diluted hydrochloric acid, extracted with chloroform, washed with water, and dried over anhydrous magnesium sulfate. After distilling off the solvent under reduced pressure, the residue was subjected to silica gel flash column chromatography (eluting solvent: chloroform / ethanol = 20/1).
And oily 5- (3,4-dimethylphenylthio)
-4- (N, N-dipentylcarbamoyl) pentanoic acid 124
to obtain mg.
IR(neat):νC=01725,1705,1635cm-1 NMR(CDC13) δ:0.83(3H,t,J=7.1Hz),0.89(3H,t,J=7.1Hz),
0.95〜1.6(12H,m),1.95〜2.1(2H,m),2.22(6H,s),
2.25〜2.5(2H,m),2.8〜3.35(7H,m),7.04(1H,d,J=
8.2Hz),7.11(1H,dd,J=1.7,8.2Hz),7.15(1H,d,J=
1.7Hz) 実施例4 実施例3と同様にして表の化合物を製造した。IR (neat): ν C = 0 1725,1705,1635 cm -1 NMR (CDC1 3 ) δ: 0.83 (3H, t, J = 7.1Hz), 0.89 (3H, t, J = 7.1Hz),
0.95 ~ 1.6 (12H, m), 1.95 ~ 2.1 (2H, m), 2.22 (6H, s),
2.25 ~ 2.5 (2H, m), 2.8 ~ 3.35 (7H, m), 7.04 (1H, d, J =
8.2Hz), 7.11 (1H, dd, J = 1.7,8.2Hz), 7.15 (1H, d, J =
1.7 Hz) Example 4 The compounds in the table were produced in the same manner as in Example 3.
参考例3 5−(3,4−ジメチルフェニルチオ)−4−(N,N−ジペ
ンチルカルバモイル)ペンタン酸メチル544mgを乾燥塩
化メチレン10mlに溶かし、−78℃で撹拌下にm−クロロ
過安息香酸(70%)308mgを少量ずつ加えたのち、2時
間反応させた。さらに1時間室温で反応後、反応液に亜
硫酸ナトリウムを加えたのち炭酸水素ナトリウム水溶液
および水で洗い、無水硫酸マグネシウムで乾燥した。減
圧下に溶媒を留去後、残留物をシリカゲルフラッシュカ
ラムクロマトグラフィー(溶出溶媒:ベンゼン/酢酸エ
チル=2/1)で精製し、油状の5−(3,4−ジメチルフェ
ニルスルホニル)−4−(N,N−ジペンチルカルバモイ
ル)ペンタン酸メチル65mgを得た。 Reference Example 3 544 mg of methyl 5- (3,4-dimethylphenylthio) -4- (N, N-dipentylcarbamoyl) pentanoate was dissolved in 10 ml of dry methylene chloride, and m-chloroperbenzoic acid was stirred at -78 ° C. After adding 308 mg (70%) little by little, the mixture was reacted for 2 hours. After reacting for 1 hour at room temperature, sodium sulfite was added to the reaction solution, washed with an aqueous solution of sodium hydrogen carbonate and water, and dried over anhydrous magnesium sulfate. After evaporating the solvent under reduced pressure, the residue was purified by silica gel flash column chromatography (eluting solvent: benzene / ethyl acetate = 2/1) to give oily 5- (3,4-dimethylphenylsulfonyl) -4-. 65 mg of methyl (N, N-dipentylcarbamoyl) pentanoate was obtained.
NMR(CDC13) δ:0.89(3H,t,J=7.1Hz),0.94(3H,t,J=7.1Hz),
1.15〜1.75(12H,m),1.85〜2.1(2H,m),2.2〜2.4(8
H,m),3.05(1H,dd,J=4.4,13.7Hz),3.1〜3.45(5H,
m),3.6〜3.75(4H,m),7.29(1H,d,J=8.2Hz),7.6〜
7.7(2H,m) 5−(3,4−ジメチルフェニルスルホニル)−4−(N,N
−ジペンチルカルバモイル)ペンタン酸メチル60mgをエ
タノール3mlに溶かし、1規定水酸化ナトリウム水溶液
0.15mlを加え、室温16時間反応させた。反応液を減圧下
に濃縮後、希塩酸を加え酸性とし、クロロホルムで抽出
し、水洗後無水硫酸マグネシウムで乾燥した。減圧下に
溶媒を留去し、残留物をシリカゲルフラッシュカラムク
ロマトグラフィー(溶出溶媒:クロロホルム/エタノー
ル=10/1)で精製後、クロロホルム−ヘキサンより再結
晶し、融点77〜79℃の5−(3,4−ジメチルフェニルス
ルホニル)−4−(N,N−ジペンチルカルバモイル)ペ
ンタン酸44mgを得た。 NMR (CDC1 3 ) δ: 0.89 (3H, t, J = 7.1Hz), 0.94 (3H, t, J = 7.1Hz),
1.15 ~ 1.75 (12H, m), 1.85 ~ 2.1 (2H, m), 2.2 ~ 2.4 (8
H, m), 3.05 (1H, dd, J = 4.4,13.7Hz), 3.1 to 3.45 (5H,
m), 3.6 to 3.75 (4H, m), 7.29 (1H, d, J = 8.2Hz), 7.6 to
7.7 (2H, m) 5- (3,4-Dimethylphenylsulfonyl) -4- (N, N
-Methyl dipentylcarbamoyl) pentanoate 60 mg was dissolved in ethanol 3 ml, and 1N sodium hydroxide aqueous solution was added.
0.15 ml was added, and the mixture was reacted at room temperature for 16 hours. The reaction solution was concentrated under reduced pressure, acidified with diluted hydrochloric acid, extracted with chloroform, washed with water, and dried over anhydrous magnesium sulfate. The solvent was distilled off under reduced pressure, and the residue was purified by silica gel flash column chromatography (eluting solvent: chloroform / ethanol = 10/1) and then recrystallized from chloroform-hexane to give 5- (5) having a melting point of 77-79 ° C. 44 mg of 3,4-dimethylphenylsulfonyl) -4- (N, N-dipentylcarbamoyl) pentanoic acid was obtained.
元素分析値:(C24H39NO5Sとして) C% H% N% 計算値 63.54 8.66 3.09 実測値 63.26 8.91 2.96 NMR(CDC13) δ:0.89(3H,t,J=7.1Hz),0.93(3H,t,J=7.1Hz),
1.1〜2.4(22H,m),3.06(1H,dd,J=4.4,13.7Hz),3.1
〜3.5(5H,m),3.67(1H,dd,J=7.7,13.7Hz),7.29(1
H,d,J=8.2Hz),7.55〜7.7(2H,m) 参考例4 5−(3,4−ジメチルフェニルスルフィニル)−4−
(N,N−ジペンチルカルバモイル)ペンタン酸メチルお
よび5−(3,4−ジメチルフェニルスルフィニル)−4
−(N,N−ジペンチルカルバモイル)ペンタン酸5−
(3,4−ジメチルフェニルチオ)−4−(N,N−ジペンチ
ルカルバモイル)ペンタン酸メチル0.55gを乾燥塩化メ
チレン10mlに溶かし、−78℃で撹拌下にm−クロロ過安
息香酸(70%)0.31gを少量ずつ加えたのち、3時間反
応させた。反応液に亜硫酸ナトリウムを加えたのち炭酸
水素ナトリウム水溶液で洗い、水洗後無水硫酸マグネシ
ウムで乾燥した。減圧下に溶媒を留去後、残留物をシリ
カゲルフラッシュカラムクロマトグラフィー(溶出溶
媒:ベンゼン/酢酸エチル=2/1)で精製し、先に溶出
する5−(3,4−ジメチルフェニルスルフィニル)−4
−(N,N−ジペンチルカルバモイル)ペンタン酸メチル
(ジアステレオマーA)0.12gと、後に溶出するジアス
テレオマーB0.36gを得た。Elemental analysis value: (as C 24 H 39 NO 5 S) C% H% N% Calculated value 63.54 8.66 3.09 Measured value 63.26 8.91 2.96 NMR (CDC1 3 ) δ: 0.89 (3H, t, J = 7.1Hz), 0.93 (3H, t, J = 7.1Hz),
1.1 to 2.4 (22H, m), 3.06 (1H, dd, J = 4.4,13.7Hz), 3.1
~ 3.5 (5H, m), 3.67 (1H, dd, J = 7.7,13.7Hz), 7.29 (1
H, d, J = 8.2 Hz), 7.55 to 7.7 (2H, m) Reference Example 4 5- (3,4-Dimethylphenylsulfinyl) -4-
Methyl (N, N-dipentylcarbamoyl) pentanoate and 5- (3,4-dimethylphenylsulfinyl) -4
-(N, N-dipentylcarbamoyl) pentanoic acid 5-
0.55 g of methyl (3,4-dimethylphenylthio) -4- (N, N-dipentylcarbamoyl) pentanoate was dissolved in 10 ml of dry methylene chloride, and m-chloroperbenzoic acid (70%) was stirred at -78 ° C. After adding 0.31 g little by little, the mixture was reacted for 3 hours. Sodium sulfite was added to the reaction solution, washed with an aqueous solution of sodium hydrogen carbonate, washed with water, and dried over anhydrous magnesium sulfate. After the solvent was distilled off under reduced pressure, the residue was purified by silica gel flash column chromatography (eluting solvent: benzene / ethyl acetate = 2/1) and eluted first with 5- (3,4-dimethylphenylsulfinyl)- Four
0.12 g of methyl-(N, N-dipentylcarbamoyl) pentanoate (diastereomer A) and 0.36 g of diastereomer B, which was eluted later, were obtained.
性状:油状 IR(neat):νC=O1730,1630cm-1 νSO1045cm-1 NMR(CDC13) δ:0.90(3H,t,J=6.6Hz),0.93(3H,t,J=6.6Hz),
1.1〜2.45(22H,m),2.76(1H,dd,J=3.3,12.1Hz),3.1
〜3.5(6H,m),3.65(3H,s),7.2〜7.45(3H,m) 〔ジアステレオマーB〕 性状:油状 IR(neat):νC=O1735,1635cm-1 νSO1045cm-1 NMR(CDC13) δ:0.87(3H,t,J=7.1Hz),0.93(3H,t,J=7.1Hz),
1.15〜1.65(12H,m),2.1〜2.5(10H,m),2.82(1H,dd,
J=9.3,13.2Hz),2.97(1H,dd,J=3.8,13.2Hz),3.1〜
3.45(5H,m),3.68(3H,s),7.2〜7.45(3H,m) 5−(3,4−ジメチルフェニルスルフィニル)−4−
(N,N−ジペンチルカルバモイル)ペンタン酸メチル
(ジアステレオマーA)120mgをエタノール3mlに溶か
し、1規定水酸化ナトリウム水溶液0.28mlを加え室温16
時間反応させた。反応液を減圧下に濃縮後、希塩酸を加
え酸性とし、クロロホルムで抽出し、水洗後無水硫酸マ
グネシウムで乾燥した。減圧下に溶媒を留去し、残留物
をシリカゲルフラッシュカラムクロマトグラフィー(溶
出溶媒:クロロホルム/エタノール=10/1)で精製し、
融点50〜54℃の5−(3,4−ジメチルフェニルスルフィ
ニル)−4−(N,N−ジペンチルカルバモイル)ペンタ
ン酸(ジアステレオマーA)90mgを得た。Property: Oily IR (neat): ν C = O 1730,1630 cm −1 ν SO 1045 cm −1 NMR (CDC1 3 ) δ: 0.90 (3H, t, J = 6.6Hz), 0.93 (3H, t, J = 6.6) Hz),
1.1 to 2.45 (22H, m), 2.76 (1H, dd, J = 3.3,12.1Hz), 3.1
~3.5 (6H, m), 3.65 (3H, s), 7.2~7.45 (3H, m) [diastereomer B] Property: oil IR (neat): ν C = O 1735,1635cm -1 ν SO 1045cm - 1 NMR (CDC1 3) δ: 0.87 (3H, t, J = 7.1Hz), 0.93 (3H, t, J = 7.1Hz),
1.15 ~ 1.65 (12H, m), 2.1 ~ 2.5 (10H, m), 2.82 (1H, dd,
J = 9.3, 13.2Hz), 2.97 (1H, dd, J = 3.8, 13.2Hz), 3.1 ~
3.45 (5H, m), 3.68 (3H, s), 7.2 to 7.45 (3H, m) 5- (3,4-dimethylphenylsulfinyl) -4-
120 mg of methyl (N, N-dipentylcarbamoyl) pentanoate (diastereomer A) was dissolved in 3 ml of ethanol, 0.28 ml of 1N aqueous sodium hydroxide solution was added, and room temperature 16
Reacted for hours. The reaction solution was concentrated under reduced pressure, acidified with diluted hydrochloric acid, extracted with chloroform, washed with water, and dried over anhydrous magnesium sulfate. The solvent was distilled off under reduced pressure, and the residue was purified by silica gel flash column chromatography (eluting solvent: chloroform / ethanol = 10/1),
90 mg of 5- (3,4-dimethylphenylsulfinyl) -4- (N, N-dipentylcarbamoyl) pentanoic acid (diastereomer A) with a melting point of 50-54 ° C were obtained.
元素分析値:(C24H39NO4Sとして) C% H% N% 計算値 65.87 8.98 3.20 実測値 65.52 9.24 3.19 IR(KBr):νC=O1720,1630cm-1 NMR(CDC13) δ:0.90(6H,t,J=6.6Hz),1.2〜2.15(14H,m),2.25
〜2.4(8H,m),2.90(1H,dd,J=3.3,12.1Hz),3.1〜3.5
(6H,m),7.2〜7.45(3H,m)Elemental analysis value: (as C 24 H 39 NO 4 S) C% H% N% Calculated value 65.87 8.98 3.20 Measured value 65.52 9.24 3.19 IR (KBr): ν C = O 1720,1630cm -1 NMR (CDC1 3 ) δ : 0.90 (6H, t, J = 6.6Hz), 1.2 to 2.15 (14H, m), 2.25
~ 2.4 (8H, m), 2.90 (1H, dd, J = 3.3, 12.1Hz), 3.1 ~ 3.5
(6H, m), 7.2 ~ 7.45 (3H, m)
───────────────────────────────────────────────────── フロントページの続き (72)発明者 阪 正昭 長野県松本市野溝木工1―2―34 キッセ イ薬品第二青友寮 (72)発明者 小林 通洋 長野県東筑摩郡明科町大字中川手3158番地 審査官 脇村 善一 ─────────────────────────────────────────────────── ─── Continuation of the front page (72) Masaaki Saka, Masaaki Saka 1-2-34 Nomizo Woodwork, Matsumoto-shi, Nagano Kissei Yakuhin Dairyo Dormitory (72) Inventor Toyohiro Kobayashi 3158 Nakagawate, Meishina-cho, Higashichikuma-gun, Nagano Prefecture Address Examiner Zenichi Wakimura
Claims (1)
れぞれ炭素数1〜10のアルキル基であり、R3は水素原子
または炭素数1〜4のアルキル基であり、Xは炭素数1
〜3のアルキル基、ニトロ基およびアセチル基の中から
選ばれる基であり、nは1または2である)で表される
フェニルチオアルキルカルボン酸誘導体。1. A general formula (R 1 and R 2 in the formula may be the same or different and each is an alkyl group having 1 to 10 carbon atoms, R 3 is a hydrogen atom or an alkyl group having 1 to 4 carbon atoms, and X is a carbon atom. Number 1
To a alkyl group, a nitro group and an acetyl group, wherein n is 1 or 2).
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP21189090A JPH07119207B2 (en) | 1990-08-10 | 1990-08-10 | Phenylthioalkylcarboxylic acid derivative |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP21189090A JPH07119207B2 (en) | 1990-08-10 | 1990-08-10 | Phenylthioalkylcarboxylic acid derivative |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH0495061A JPH0495061A (en) | 1992-03-27 |
| JPH07119207B2 true JPH07119207B2 (en) | 1995-12-20 |
Family
ID=16613336
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP21189090A Expired - Lifetime JPH07119207B2 (en) | 1990-08-10 | 1990-08-10 | Phenylthioalkylcarboxylic acid derivative |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH07119207B2 (en) |
-
1990
- 1990-08-10 JP JP21189090A patent/JPH07119207B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0495061A (en) | 1992-03-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA05004064A (en) | Alpha-phenyl acetanilide derivatives having an acat inhibiting activity and the therapeutic application thereof. | |
| JPH07119207B2 (en) | Phenylthioalkylcarboxylic acid derivative | |
| JP2520777B2 (en) | Arylthioalkylcarboxylic acid derivatives | |
| JPH07119205B2 (en) | Phenylthioalkylcarboxylic acid derivative | |
| JPH07119209B2 (en) | Naphthylthioalkylcarboxylic acid derivatives | |
| JPH07119206B2 (en) | Dichlorophenylthioalkylcarboxylic acid derivative | |
| JP2520776B2 (en) | Naphthylthioalkylcarboxylic acid derivatives | |
| JP3207017B2 (en) | Method for producing benzylsuccinic acid derivative and intermediate for producing the same | |
| AU600838B2 (en) | Process for the preparation of dextrorotatory 3-(3-pyridyl)-1H, 3H-pyrrolo(1,2-c)-7-thiazolecarboxylic acid | |
| JPH07119208B2 (en) | Naphthylthioalkylcarboxylic acid derivatives | |
| JP3207018B2 (en) | Method for producing benzylsuccinic acid derivative and intermediate for producing the same | |
| JPH07215952A (en) | Catechol derivative | |
| KR100426534B1 (en) | An improved synthetic method of azelastine | |
| JPH07119204B2 (en) | Phenylsulfinylalkylcarboxylic acid derivative | |
| JP2523026B2 (en) | α, β-Unsaturated ketone and ketoxime derivatives | |
| JPH0827132A (en) | Production of 5-oxazolones | |
| JPH07119199B2 (en) | Phenylsulfonylalkylcarboxylic acid derivative | |
| JPH07119203B2 (en) | Phenylsulfinylalkylcarboxylic acid derivative | |
| JPH07119202B2 (en) | Phenylsulfinylalkylcarboxylic acid derivative | |
| JPH0129793B2 (en) | ||
| JP2950680B2 (en) | 3-Amino-5-o-chlorobenzyl-4,5,6,7-tetrahydrothieno [3,2-c] pyridine-2-carboxylic acid derivative and method for producing the same | |
| JPH07119198B2 (en) | Phenylsulfonylalkylcarboxylic acid derivative | |
| JPH07119197B2 (en) | Phenylsulfonylalkylcarboxylic acid derivative | |
| JP2520318B2 (en) | Sulfonylalkylcarboxylic acid derivative | |
| JPH083102A (en) | Fluorine-containing dehydroabietic acid derivative |